Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Bordeaux – page 62

1 164 clinical trials in Bordeaux, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Bordeaux at a glance
1 164
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 164 trials in Bordeaux

Open in trial search

Prostate cancer

Not recruiting

Study on Apalutamide with Radiotherapy and Hormone Therapy for High-Risk Prostate Cancer Patients with Rising PSA After Surgery

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Unicancer

Ischaemic stroke+1

Not recruiting

Study of cangrelor with mechanical thrombectomy in patients with acute ischemic stroke selected by perfusion imaging

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cangrelor Tetrasodium
  • Sponsor:Fondation A De Rothschild

Neuroblastoma

Not recruiting

Study on the Safety of Lutetium (177Lu) Oxodotreotide with Arginine and Lysine in Children with Refractory or Recurrent Neuroblastoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Lysine Hydrochloride
  • Sponsor:Oncopole Claudius Regaud

Study of IDRX-42 for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:[4-(Methyl-1H-Pyrazol-4-Yl)-Benzyl] (6[7-(3-Pyrrolidin-1-Yl-Propoxy)-Imidazo[1,2-A] Pyridin-3-Yl]-Pyrimidin-4-Yl]-Amine
  • Sponsor:Idrx Inc.

Glioma

Not recruiting

Study of Abemaciclib and Temozolomide for Children and Young Adults with Newly Diagnosed High-Grade Glioma After Radiotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Study on Capivasertib and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB

Long-Term Safety Study of Avalglucosidase Alfa for Patients with Pompe Disease in France

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Avalglucosidase Alfa
  • Sponsor:Sanofi Winthrop Industrie

Neoplasm malignant

Not recruiting

Study on the Safety and Effectiveness of Tecaginlimab and Pembrolizumab with Radiotherapy for Patients with Metastatic Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Prostate cancer

Not recruiting

Study on Darolutamide with Radiation Therapy for Patients with Intermediate Unfavorable Risk Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Institut Bergonie

Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:LYSARC

Study on Ceralasertib and Trastuzumab Deruxtecan for Patients with Non-Small Cell Lung Cancer After Anti-PD-1/PD-L1 Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Endometrial cancer

Not recruiting

Study Comparing Sentinel Node Policy with Current Staging Protocols in Early Stage Endometrial Cancer Using Patent Blue, Technetium (99mTc) Rheniumsulfide, and Indocyanine Green

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Indocyanine Green
  • Sponsor:Centre Oscar Lambret

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Bordeaux

What the registry says about research in the country

01 Autoimmune & Inflammatory Conditions

Innovative research focusing on psoriatic arthritis and hidradenitis suppurativa, evaluating new therapeutic combinations and treatment strategies. Studies explore the effectiveness of targeted therapies and novel approaches like fecal microbiota transplantation.

  • Psoriatic Arthritis Treatment
  • Inflammatory Skin Conditions
  • Myasthenia Gravis Management

Clinical trials aim to improve patient outcomes through combination therapies and innovative treatment approaches.

02 Oncology Research

Comprehensive studies investigating treatments for various cancers, including head and neck squamous cell carcinoma, endometrial cancer, and bladder cancer. Research focuses on immunotherapy combinations and targeted treatments.

  • Advanced Cancer Therapies
  • Immunotherapy Approaches
  • Targeted Treatment Strategies

Trials evaluate novel drug combinations and therapeutic approaches for better cancer treatment outcomes.

03 Transplant Medicine

Ground-breaking research in kidney transplantation, focusing on preventing rejection and improving long-term outcomes. Studies evaluate new immunosuppressive strategies and antibody-mediated rejection treatments.

  • Transplant Rejection Prevention
  • Immunosuppressive Therapies
  • Long-term Outcome Studies

Research aims to enhance transplant success rates and patient quality of life.

04 Neurological & Mental Health

Studies examining multiple sclerosis, narcolepsy, and major depressive disorder. Research investigates neuroinflammation patterns and innovative treatment approaches.

  • Brain Inflammation Studies
  • Sleep Disorders
  • Depression Treatment

Trials focus on understanding disease mechanisms and developing targeted therapies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.